Six patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2031. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2031
Next term end
5
Patent families
When these terms end
Each bar runs from grant to computed term end. 2014 to 2044.
US 12,544,360
Pharmaceutical Composition for Preventing or Treating Coronavirus DISEASE-19
Feb 21, 2044
20202026203220382044
3 pending applications: term is not computable until grant.Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Apr 2032 · High confidence
Also notable
Ends Mar 2031 · High confidence
Also notable
Ends Jun 2035 · High confidence
Anti-Inflammation Compounds
US 9,029,389
The most cited patent in this portfolio, cited by 26 later US patents, top 25% of utility patents granted in 2015 in our data. Protection runs to 2032.
Anti-Infective Compounds
US 8,865,734
Cited by 21 later US patents, top 25% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2031.
Anti-Infective Compounds
US 11,279,714
Granted 2022. Computed term ends 2035.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
- 1 term has ended since Aug 16, 2026
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| Anti-Infective Compounds (2016) | 2 in force | to Jun 2035 |
| Pharmaceutical Composition for Preventing or Treating Coronavirus DISEASE-19 | 1 in force | to Feb 2044 |
| 2-Methoxyestradiol Derivatives and Medical Uses Thereof | 1 in force | to May 2043 |
| Anti-Inflammation Compounds | 1 in force | to Apr 2032 |
| Anti-Infective Compounds (2012) | 1 in force | to Mar 2031 |
Patents held now
Soonest term end first.
Showing 1 to 6 of 6
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,865,734 | Anti-Infective Compounds held by Institut Pasteur Korea and Institut National de la Sante et de la Recherche Medicale (Inserm) In force · High confidence | In force | High confidence | |
| US 9,029,389 | Anti-Inflammation Compounds In force · High confidence | In force | High confidence | |
| US 11,279,714 | Anti-Infective Compounds In force · High confidence | In force | High confidence | |
| US 12,227,524 | Anti-Infective Compounds In force · Medium confidence | In force | Medium confidence | |
| US 12,570,685 | 2-Methoxyestradiol Derivatives and Medical Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,544,360 | Pharmaceutical Composition for Preventing or Treating Coronavirus DISEASE-19 In force · High confidence | In force | High confidence |
Also on record, not counted in the 6: 6 patents ended · 3 applications pending · 6 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.